(NASDAQ: CELC) Celcuity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Celcuity's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CELC's revenue for 2025 to be $264,875,744, with the lowest CELC revenue forecast at $264,875,744, and the highest CELC revenue forecast at $264,875,744. On average, 3 Wall Street analysts forecast CELC's revenue for 2026 to be $1,810,614,907, with the lowest CELC revenue forecast at $921,389,195, and the highest CELC revenue forecast at $3,553,118,909.
In 2027, CELC is forecast to generate $10,757,360,752 in revenue, with the lowest revenue forecast at $7,661,341,698 and the highest revenue forecast at $14,140,580,790.